Market Research Logo

Non-Hodgkin Lymphoma - Pipeline Review, H1 2018

Non-Hodgkin Lymphoma - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H1 2018, provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape.

Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms depend on what area of the body is affected by the cancer and how fast the cancer is growing. Symptoms may include night sweats (soaking the bed sheets and pajamas even though the room temperature is not too hot),fever and chills that come and go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas, weight loss, coughing or shortness of breath if the cancer affects the thymus gland or lymph nodes in the chest, putting pressure on the windpipe (trachea) or other airway, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if the cancer affects the brain. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma (Oncology)

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Hodgkin Lymphoma (Oncology) pipeline guide

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 4, 30, 160, 136, 1, 5, 126, 15 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 19, 22, 17 and 4 molecules, respectively.

Non-Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Non-Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Non-Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Non-Hodgkin Lymphoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Non-Hodgkin Lymphoma - Overview
Non-Hodgkin Lymphoma - Therapeutics Development
Non-Hodgkin Lymphoma - Therapeutics Assessment
Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development
Non-Hodgkin Lymphoma - Drug Profiles
Non-Hodgkin Lymphoma - Dormant Projects
Non-Hodgkin Lymphoma - Discontinued Products
Non-Hodgkin Lymphoma - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Non-Hodgkin Lymphoma, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Non-Hodgkin Lymphoma - Pipeline by 3SBio Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by 4SC AG, H1 2018
Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H1 2018
Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by ACEA Biosciences Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics SA, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Affimed GmbH, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Affitech A/S, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Agios Pharmaceuticals Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Aileron Therapeutics Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by AlfaSigma SpA, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Allinky Biopharma, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Altor BioScience Corp, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Amgen Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Angimmune LLC, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Aptevo Therapeutics Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Ariad Pharmaceuticals Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by ArQule Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Arrien Pharmaceuticals LLC, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Arven Ilac, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Asana BioSciences LLC, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Autolus Ltd, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Bantam Pharmaceutical LLC, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H1 2018
Non-Hodgkin Lymphoma - Pipeline by BeiGene Ltd, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Bio-Path Holdings Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Biocon Ltd, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Biogen Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by BioInvent International AB, H1 2018
Non-Hodgkin Lymphoma - Pipeline by BioLineRx Ltd, H1 2018
Non-Hodgkin Lymphoma - Pipeline by BioSight Ltd, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Biothera Pharmaceutical Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Boston Biomedical Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Brickell Biotech Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Co, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by CARsgen Therapeutics Ltd, H1 2018
Non-Hodgkin Lymphoma - Pipeline by CBT Pharmaceuticals Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Celgene Corp, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Cell Medica Ltd, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Cell Source Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Cell>Point LLC, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Celldex Therapeutics Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Cellectar Biosciences Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Cellectis SA, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Celleron Therapeutics Ltd, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Cellestia Biotech AG, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Celltrion Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Centrose LLC, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Cerenis Therapeutics Holding SA, H1 2018
Non-Hodgkin Lymphoma - Pipeline by CerRx Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Cielo Therapeutics Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Clevexel Pharma SAS, H1 2018
Non-Hodgkin Lymphoma - Pipeline by Corvus Pharmaceuticals Inc, H1 2018
Non-Hodgkin Lymphoma - Pipeline by CrystalGenomics Inc, H1 2018
List of Figures
Number of Products under Development for Non-Hodgkin Lymphoma, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report